Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations

Clinical Infectious Diseases

Volumn 54, Issue 1, 2012, Pages 131-140

  Von Wyl, Viktor ^a,b   Yerly, Sabine ^c   Böni, Jürg ^d   Shah, Cyril ^d   Cellerai, Cristina ^e   Klimkait, Thomas ^f   Battegay, Manuel ^g   Bernasconi, Enos ^h   Cavassini, Matthias ^e   Furrer, Hansjakob ⁱ   Hirschel, Bernard ^c   Vernazza, Pietro L ^j   Ledergerber, Bruno ^a   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG SCREENING; FEMALE; GENOTYPIC DRUG RESISTANCE TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84555206693     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir728     Document Type: Article

References (26)

1. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-9. (Pubitemid 27478210)
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60. (Pubitemid 28135961)
3. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-85. (Pubitemid 351920631)
4. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-90. (Pubitemid 47403067)
5. Lampe FC, Smith CJ, Madge S, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167:692-700. (Pubitemid 46598462)
6. Ledergerber B, Cavassini M, Battegay M, et al. Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med 2011; 12:279-88.
7. von Wyl V, Yerly S, Burgisser P, et al. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis 2009; 48:979-87.
8. Bannister WP, Cozzi-Lepri A, Kjaer J, et al. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 2011; 66:901-11.
9. Long-term probability of detecting drug-resistant HIV in treatmentnaive patients initiating combination antiretroviral therapy. Clin Infect Dis 2009; 50:1275-85.
10. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort Study. Int J Epidemiol 2010; 39:1179-89.
11. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170:57-65.
12. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8. (Pubitemid 29126872)
13. Kouyos RD, von Wyl V, Yerly S, et al. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 2010; 201:1488-97.
14. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 2001; 286:171-9. (Pubitemid 32640848)
15. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16:1967-9.
16. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-63.
17. Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21:2223-9. (Pubitemid 350287221)
18. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
19. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 2006; 14:827-43. (Pubitemid 44223106)
20. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-33.
21. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106. (Pubitemid 351679596)
22. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-22.
23. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60. (Pubitemid 43113030)
24. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med 2011; 154:445-56.
25. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 2009; 14:995-1000.
26. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50:98-105.